Predictive Biosciences presents on next-generation sequencing solutions
Molecular diagnostic test developer Predictive Biosciences presented at the NGx: Applying Next-Generation Sequencing conference in Providence, RI on August 14.
Molecular diagnostic test developer Predictive Biosciences (Lexington, MA) presented at the NGx: Applying Next-Generation Sequencing conference in Providence, RI on August 14.
In a presentation titled "A Cost Effective Assay for Multiplexing Protein and DNA Biomarkers on a Single Analytical Platform," Anthony P. Shuber, CTO, discussed the company's use of next-generation sequencing (NGS) to simultaneously detect protein and DNA biomarkers on one platform. The method can eliminate the need to perform separate procedures for protein and DNA while decreasing assay complexity and cost, says the company. Shuber also chaired a technical session at the meeting on tips and tricks for NGS application.
The company recently launched a sequencing-based version of its CertNDx bladder cancer assay, which uses a NGS platform to detect FGFR3 mutations that are indicative of bladder cancer. Marc Schneebaum, CEO, notes that the approach could be applied to other cancer markers and bodily fluids to improve clinical performance and patient management.
Shuber will also be presenting "Incorporating Next-Gen Sequencing into the Clinical Environment" at the upcoming Next Generation Dx Summit in Washington, DC, on August 21. The presentation will focus on the recently developed assay that uses NGS to detect single mutant molecules of FGFR3 in urine. The assay performance resulted in mutation detection in urine that is >90% concordant with that found in tissue.
Follow us on Twitter, 'like' us on Facebook, and join our group on LinkedIn
Laser Focus World has gone mobile: Get all of the mobile-friendly options here.
Subscribe now to BioOptics World magazine; it's free!